By a News Reporter-Staff News Editor at AIDS Vaccine Week -- Data detailed on Immune System Diseases and Conditions have been presented. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "Failure to induce synthesis of neutralizing Abs to the CD4 binding determinant (CD4BD) of gp120, a central objective in HIV vaccine research, has been alternately ascribed to insufficient immunogen binding to Abs in their germline V region configuration expressed as BCRs, insufficient adaptive mutations in Ab V regions, and conformational instability of gp120. We employed peptide analogs of gp120 residues 421-433 within the CD4BD (CD4BD(core)) to identify Abs produced without prior exposure to HIV (constitutive Abs)."
Our news journalists obtained a quote from the research from the University of Texas School of Medicine, "The CD4BD(core) peptide was recognized by single-chain Fv fragments from noninfected humans with lupus that neutralized genetically diverse strains belonging to various HIV subtypes. Replacing the framework region (FR) of a V(H)4-family single-chain Fv with the corresponding V(H)3-family FRs from single-chain Fv JL427 improved the CD4BD(core) peptide-binding activity, suggesting a CD4BD(core) binding site outside the pocket formed by the CDRs. Replacement mutations in the FR site vicinity suggested the potential for adaptive improvement. A very small subset of serum CD4BD(core)-specific serum IgAs from noninfected humans without autoimmune disease isolated by epitope-specific chromatography neutralized the virus potently. A CD4BD(core)-specific, HIV neutralizing murine IgM with H and L chain V regions (V(H) and V(L) regions) free of immunogen-driven somatic mutations was induced by immunization with a CD4BD(core) peptide analog containing an electrophilic group that binds B cells covalently."
According to the news editors, the research concluded: "The studies indicate broad and potent HIV neutralization by constitutive Abs as an innate, germline-encoded activity directed to the superantigenic CD4BD(core) epitope that is available for amplification for vaccination against HIV."
For more information on this research see: Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine. Journal of Immunology, 2012;189(11):5367-81. (The American Association of Immunologists - www.aai.org; Journal of Immunology - www.jimmunol.org)
The news correspondents report that additional information may be obtained from S.A. Planque, Dept. of Pathology and Laboratory Medicine, Chemical Immunology Research Center, University of Texas Medical School at Houston, Houston, TX 77030, United States. Additional authors for this research include Y. Mitsuda, Y. Nishiyama, S. Karle, S. Boivin, M. Salas, M.K. Morris, M. Hara, G. Liao, R.J. Massey, C.V. Hanson and S. Paul (see also Immune System Diseases and Conditions).
Keywords for this news article include: Antibodies, Texas, Houston, Genetics, HIV/AIDS, Peptides, Vaccines, Virology, Immunology, Proteomics, RNA Viruses, Retroviridae, United States, Glycoproteins, Superantigens, Blood Proteins, HIV Infections, Glycoconjugates, Immunoglobulins, Vertebrate Viruses, Biological Products, Primate Lentiviruses.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC